GenEdit™ Commercial Sales Begin
August 1, 2013
Posted by: First Biotech
First Biotech’s groundbreaking GenEdit™ site-directed DNA mutagenesis kit has made its commercial debut. The kit is a product of several years of academic and industrial research and development. A successful round of pre-release tests have enabled First Biotech to release the GenEdit™ kit according to a planned schedule of August 1, 2013.
“Testing the pre-release version of the GenEdit™ kit by several research laboratories across the United States helped us fine-tune it for a wider range of DNA mutagenesis projects. We received a lot of interest in, and positive feedback for the new technology that encouraged us to move forward to our next phase of commercialization” says Dr. Louay Hallak, First Biotech’s founder and president. He went on to thank everyone who participated and provided their feedback during the testing period.
The GenEdit™ kit has been released in three versions of 8, 16 and 24 reaction formats and is now available for direct purchase through First Biotech.